Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation

被引:225
作者
Leri, A
Franco, S
Zacheo, A
Barlucchi, L
Chimenti, S
Limana, F
Nadal-Ginard, B
Kajstura, J
Anversa, P
Blasco, MA [1 ]
机构
[1] New York Med Coll, Dept Med, Cardiovasc Res Inst, Valhalla, NY 10595 USA
[2] CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain
关键词
aging; heart failure; p53; telomerase; telomeres;
D O I
10.1093/emboj/cdg013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiac failure is a frequent cause of death in the aging human population. Telomere attrition occurs with age, and is proposed to be causal for the aging process. To determine whether telomere shortening leads to a cardiac phenotype, we studied heart function in the telomerase knockout mouse, Terc-/-. We studied Terc-/- mice at the second, G2, and fifth, G5, generation. Telomere shortening in G2 and G5 Terc-/- mice was coupled with attenuation in cardiac myocyte proliferation, increased apoptosis and cardiac myocyte hypertrophy. On, a single-cell basis, telomere shortening was coincidental with increased expression of p53, indicating the presence of dysfunctional telomeres in cardiac myocytes from G5 Terc-/- mice. The impairment in cell division, the enhanced cardiac myocyte death and cellular hypertrophy, are concomitant with ventricular dilation, thinning of the wall and cardiac dysfunction. Thus, inhibition of cardiac myocyte replication provoked by telomere shortening, results in de-compensated eccentric hypertrophy and heart failure in mice. Telomere shortening with age could also contribute to cardiac failure in humans, opening the possibility for new therapies.
引用
收藏
页码:131 / 139
页数:9
相关论文
共 32 条
  • [1] Myocyte renewal and ventricular remodelling
    Anversa, P
    Nadal-Ginard, B
    [J]. NATURE, 2002, 415 (6868) : 240 - 243
  • [2] ANVERSA P, 2001, HDB PHYSL 2, V1, P75
  • [3] Evidence that human cardiac myocytes divide after myocardial infarction (Publication with Expression of Concern. See vol. 379, pg. 1870, 2018)
    Beltrami, AP
    Urbanek, K
    Kajstura, J
    Yan, SM
    Finato, N
    Bussani, R
    Nadal-Ginard, B
    Silvestri, F
    Leri, A
    Beltrami, CA
    Anversa, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (23) : 1750 - 1757
  • [4] Telomerase beyond telomeres
    Blasco, MA
    [J]. NATURE REVIEWS CANCER, 2002, 2 (08) : 627 - 632
  • [5] Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
    Blasco, MA
    Lee, HW
    Hande, MP
    Samper, E
    Lansdorp, PM
    DePinho, RA
    Greider, CW
    [J]. CELL, 1997, 91 (01) : 25 - 34
  • [6] Extension of life-span by introduction of telomerase into normal human cells
    Bodnar, AG
    Ouellette, M
    Frolkis, M
    Holt, SE
    Chiu, CP
    Morin, GB
    Harley, CB
    Shay, JW
    Lichtsteiner, S
    Wright, WE
    [J]. SCIENCE, 1998, 279 (5349) : 349 - 352
  • [7] New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin
    Chan, SWL
    Blackburn, EH
    [J]. ONCOGENE, 2002, 21 (04) : 553 - 563
  • [8] p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis
    Chin, L
    Artandi, SE
    Shen, Q
    Tam, A
    Lee, SL
    Gottlieb, GJ
    Greider, CW
    DePinho, RA
    [J]. CELL, 1999, 97 (04) : 527 - 538
  • [9] Telomerase in the human organism
    Collins, K
    Mitchell, JR
    [J]. ONCOGENE, 2002, 21 (04) : 564 - 579
  • [10] Protection of mammalian telomeres
    de Lange, T
    [J]. ONCOGENE, 2002, 21 (04) : 532 - 540